Intranasal Immunotherapy with Allergen-Loaded Extracellular Vesicles from Mast Cells Alleviates Allergic Asthma Inflammation in a Murine Model.

ABSTRACT: Allergen immunotherapy (AIT) is the only treatment that can alter the course of allergic diseases by inducing immune tolerance through long-term, repeated low-dose allergen exposure. Nonetheless, AIT persistently faces challenges necessitating resolution, particularly in relation to treatment duration, the incidence of adverse reactions, and patient adherence. Extracellular vesicles (EVs) are promising drug delivery carriers for medications, vaccines, and targeted antibodies. Previously, we demonstrated that intravenous bone marrow-derived mast cell EVs (BMMC-EVs) can reduce allergic airway inflammation in asthmatic mice by interacting with free IgE. This study explores the potential of intranasally administered BMMC-EVs loaded with dermatophagoides farinae extracts to induce local immune

SUBMITTER: Huanjin L 

PROVIDER: S-EPMC12722274 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature